Abbott und Cristiano Ronaldo arbeiten zusammen, um junge Menschen zum Blut spenden anzuregen
Blut ist DER Saft des Lebens, doch vielen Menschen wird dies erst bewusst, wenn die Lage kritisch ist.
OTS0001
Abbotts wegweisende Plattform für die Diagnostik von Infektionskrankheiten, IRIDICA, jetzt auch in Europa
Abbott kündigte heute an, dass seine innovative Diagnoseplattform IRIDICA jetzt in Europa und anderen Staaten mit CE-Kennzeichnung zugänglich ist.
OTS0024
Abbott to Separate into Two Leading Companies in Diversified Medical Products and Research-Based Pharmaceuticals
Today Abbott announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals.
OTE0012
Abbott Confirms Long-Term Commitment to HIV Care with the Planned Development of New Formulations
Abbott announced today that it plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with …
OTE0005
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
OTE0006
Twenty-Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
Imagine delaying a life-saving surgery or being afraid to receive or donate blood for fear of contracting HIV (http://www.who.int/hiv/en/).
OTE0004
Abbott Completes Acquisition of Solvay Pharmaceuticals
Abbott today announced that it has completed its EUR 4.5 billion (US$6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of …
OTE0002
Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries
Today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend the suspension of marketing authorizations for all anti-obesity medicines containing …
OTE0003
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe.
OTE0005
New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark
Abbott announced today it has received CE Marking (Conformite Europeene) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non-invasive DNA assay that …
OTE0002
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
- New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients
OTE0008
Abbott to Acquire Solvay Pharmaceuticals Business
- Diversifies Abbott's pharmaceutical products, expanding international growth platform
OTE0001
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.
OTE0007
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
- Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte
OTE0005
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
At One Year, XIENCE V Demonstrates:
OTE0004
